Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026
Same author

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

HemaSphere·2026
Same author

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Blood cancer journal·2026
Same author

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

HemaSphere·2026
Same author

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Bone marrow transplantation·2026
Same author

Rethinking Cardiovascular Events, End Points, and Surveillance in Oncology Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

Related Experiment Video

Updated: Jul 9, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.0K

Classic Hodgkin lymphoma.

Justine Kahn1, Bouthaina Dabaja2, Susan Wu2

  • 1Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, USA.

Hematological Oncology
|December 1, 2023
PubMed
Summary
This summary is machine-generated.

Classic Hodgkin lymphoma (HL) survival has greatly improved due to chemotherapy and radiation. Ongoing research focuses on targeted therapies and reducing long-term side effects for young adults.

Keywords:
AYAHodgkinlymphoma

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K

Related Experiment Videos

Last Updated: Jul 9, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.0K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Classic Hodgkin lymphoma (HL) is a rare cancer primarily affecting adolescents and young adults.
  • Significant survival improvements have been achieved since the 1960s with combination chemotherapy and early radiation techniques.
  • Current 5-year survival rates for HL approach 90%.

Purpose of the Study:

  • To review the advancements in Hodgkin lymphoma treatment.
  • To highlight the ongoing challenges in managing treatment-associated late toxicities.
  • To emphasize the need for research into reducing long-term side effects in HL survivors.

Main Methods:

  • Review of historical and current therapeutic strategies for Hodgkin lymphoma.
  • Analysis of survival outcomes and treatment-associated toxicities.
  • Exploration of recent biological insights and targeted therapies.

Main Results:

  • Combination chemotherapy and radiation have dramatically improved HL outcomes.
  • Targeted agents and immunotherapy have further enhanced short and long-term results.
  • Despite high survival rates, long-term survivors face significant treatment-related late effects.

Conclusions:

  • Hodgkin lymphoma treatment has seen remarkable progress, leading to high survival rates.
  • Reducing late toxicities in long-term survivors is a critical priority.
  • Future research should balance therapeutic efficacy with minimizing long-term adverse effects.